View ValuationNorthwest Biotherapeutics 향후 성장Future 기준 점검 2/6Northwest Biotherapeutics의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장24.7%매출 성장률165.5%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트13 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 09Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for GlioblastomaNorthwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls.공고 • Apr 01Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Nov 20Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United States공고 • Aug 28Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings. The transaction is expected to close as soon as certain legal conditions are fulfilled.공고 • Aug 19Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanNorthwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.공고 • Jul 02Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 17,727,273 Price\Range: $0.22공고 • Jun 12Northwest Biotherapeutics Announces Upcoming Presentation on Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsNorthwest Biotherapeutics announced that Dr. Marnix Bosch, its Chief Technical Officer, will make a presentation on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses" at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. Dr. Bosch will address certain factors and combinations of factors that may lead to supercharged dendritic cells with enhanced anti-tumor effects. The presentation will take place on June 16, at 2:50 p.m. The slides will be posted on the company's website after the presentation.공고 • Dec 27Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,587,302 Price\Range: $0.255 Discount Per Security: $0.019125 Transaction Features: Registered Direct Offering공고 • May 25Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024. Location: offices of gibson, dunn & crutcher llp, 1050 connecticut avenue nw, washington, dc 20036, United States공고 • Mar 22Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of DirectorsNorthwest Biotherapeutics announced that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski's term as an independent director, following Mr. Jasinowski's retirement due to health reasons as previously reported. Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees. Mr. Sarma is a longtime shareholder of NWBio. In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor. One of the companies he founded and built was American Megatrends Inc. (AMI), which became a major player in hardware, software and firmware components of PC-based systems. The company was known for developing the AMIBIOS firmware program for IBM-PC compatibility. The BIOS (Basic Input Output System) is the heart of PC-compatibility and all application programs access the BIOS in reading from or writing to peripheral units such as drives, keyboards, mouse. Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets. He was an owner for a number of years of the N.J. Devils team in the National Hockey League, and has invested in a diverse range of industries including medical and environmental companies. Mr. Sarma has been an investor in NWBio for more than a decade. Mr. Sarma received a Master's Degree in Industrial Engineering and Operations Research from Georgia Tech and a Bachelor's Degree in Mechanical Engineering from the University of Madras.공고 • Mar 03Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/01/2024, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Dec 22Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for GlioblastomaNorthwest Biotherapeutics announced that a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®?-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. GBM is the most lethal and most common form of primary brain cancer. Despite well over 400 clinical trials of a wide range of treatment agents, patient survival in newly diagnosed GBM is only 15-17 months and has not meaningful improved in 20 years; survival in recurrent GBM is only 6-8 months and has not improved in 30 years. The Company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM in patients treated with DCVax-L compared with independently selected, matched, contemporaneous, pre-specified external controls. The trial also demonstrated more than doubling of the percentage of patients alive at 5 years in newly diagnosed GBM, and more than doubling of patients alive at 3 years after tumor recurrence in recurrent GBM patients, although the numbers of patients available for comparison at late time points was small, especially in the external control populations. One of the key factors making GBM so difficult to treat is that it is an extremely heterogeneous tumor. DCVax-Direct involves essentially the same mechanism of action as DCVax-L, except that the tumor target proteins are taken up by the dendritic cells in situ in the tumor following intra-tumoral injection, rather than from tumor lysate from a surgically resected tumor tissue sample. The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors. For the GBM MAA, the Company anticipates that the review process will be a period of intensive and extensive further work involving responding to questions and requests for further information by the regulatory authority as well as preparing for and undergoing detailed inspections of the contract research organizations (CROs) that managed the trial, the Sponsor, the Trial Master File, a number of individual trial sites selected by the regulatory from among the 94 sites that participated in the trial, the GMP facility and manufacturing information.공고 • Sep 13Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory BoardNorthwest Biotherapeutics announced that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine. The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.이익 및 매출 성장 예측OTCPK:NWBO - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202739N/A-41-40112/31/2026N/AN/A-51-5013/31/20261-45-49-48N/A12/31/20251-61-46-45N/A9/30/20251-91-51-50N/A6/30/20251-84-45-45N/A3/31/20251-86-55-54N/A12/31/20241-85-58-57N/A9/30/20242-71-55-54N/A6/30/20242-76-61-59N/A3/31/20241-72-57-55N/A12/31/20232-64-57-54N/A9/30/20232-78-51-46N/A6/30/20232-87-53-48N/A3/31/20232-102-55-51N/A12/31/20222-105-56-53N/A9/30/2022157-57-55N/A6/30/20221135-51-46N/A3/31/20221169-44-38N/A12/31/20211179-44-38N/A9/30/20212-234-45-37N/A6/30/20211-474-45-38N/A3/31/20211-537-45-38N/A12/31/20201-530-39-32N/A9/30/20202-243-32-28N/A6/30/20202-56-28-26N/A3/31/202033-30-30N/A12/31/20192-21N/A-32N/A9/30/20191-33N/A-40N/A6/30/20191-18N/A-38N/A3/31/20191-43N/A-40N/A12/31/20180-54N/A-35N/A9/30/20181-76N/A-35N/A6/30/20181-108N/A-37N/A3/31/20180-93N/A-29N/A12/31/20170-74N/A-36N/A9/30/20170-77N/A-36N/A6/30/20170-86N/A-40N/A3/31/20170-92N/A-50N/A12/31/20161-86N/A-56N/A9/30/20161-79N/A-65N/A6/30/20162-24N/A-67N/A3/31/20162-74N/A-80N/A12/31/20152-115N/A-80N/A9/30/20152-133N/A-75N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NWBO 의 예상 수익 증가율이 절약률(3.5%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: NWBO 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: NWBO 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: NWBO 의 수익(연간 165.5%)이 US 시장(연간 12.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NWBO 의 수익(연간 165.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NWBO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/20 10:02종가2026/07/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Northwest Biotherapeutics, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christian OrqueraFirst Berlin Equity Research GmbHBoris PeakerOppenheimer & Co. Inc.
공고 • Jul 09Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for GlioblastomaNorthwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls.
공고 • Apr 01Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Nov 20Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United States
공고 • Aug 28Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings. The transaction is expected to close as soon as certain legal conditions are fulfilled.
공고 • Aug 19Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanNorthwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.
공고 • Jul 02Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 17,727,273 Price\Range: $0.22
공고 • Jun 12Northwest Biotherapeutics Announces Upcoming Presentation on Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsNorthwest Biotherapeutics announced that Dr. Marnix Bosch, its Chief Technical Officer, will make a presentation on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses" at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. Dr. Bosch will address certain factors and combinations of factors that may lead to supercharged dendritic cells with enhanced anti-tumor effects. The presentation will take place on June 16, at 2:50 p.m. The slides will be posted on the company's website after the presentation.
공고 • Dec 27Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,587,302 Price\Range: $0.255 Discount Per Security: $0.019125 Transaction Features: Registered Direct Offering
공고 • May 25Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024. Location: offices of gibson, dunn & crutcher llp, 1050 connecticut avenue nw, washington, dc 20036, United States
공고 • Mar 22Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of DirectorsNorthwest Biotherapeutics announced that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski's term as an independent director, following Mr. Jasinowski's retirement due to health reasons as previously reported. Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees. Mr. Sarma is a longtime shareholder of NWBio. In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor. One of the companies he founded and built was American Megatrends Inc. (AMI), which became a major player in hardware, software and firmware components of PC-based systems. The company was known for developing the AMIBIOS firmware program for IBM-PC compatibility. The BIOS (Basic Input Output System) is the heart of PC-compatibility and all application programs access the BIOS in reading from or writing to peripheral units such as drives, keyboards, mouse. Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets. He was an owner for a number of years of the N.J. Devils team in the National Hockey League, and has invested in a diverse range of industries including medical and environmental companies. Mr. Sarma has been an investor in NWBio for more than a decade. Mr. Sarma received a Master's Degree in Industrial Engineering and Operations Research from Georgia Tech and a Bachelor's Degree in Mechanical Engineering from the University of Madras.
공고 • Mar 03Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/01/2024, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Dec 22Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for GlioblastomaNorthwest Biotherapeutics announced that a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®?-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. GBM is the most lethal and most common form of primary brain cancer. Despite well over 400 clinical trials of a wide range of treatment agents, patient survival in newly diagnosed GBM is only 15-17 months and has not meaningful improved in 20 years; survival in recurrent GBM is only 6-8 months and has not improved in 30 years. The Company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM in patients treated with DCVax-L compared with independently selected, matched, contemporaneous, pre-specified external controls. The trial also demonstrated more than doubling of the percentage of patients alive at 5 years in newly diagnosed GBM, and more than doubling of patients alive at 3 years after tumor recurrence in recurrent GBM patients, although the numbers of patients available for comparison at late time points was small, especially in the external control populations. One of the key factors making GBM so difficult to treat is that it is an extremely heterogeneous tumor. DCVax-Direct involves essentially the same mechanism of action as DCVax-L, except that the tumor target proteins are taken up by the dendritic cells in situ in the tumor following intra-tumoral injection, rather than from tumor lysate from a surgically resected tumor tissue sample. The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors. For the GBM MAA, the Company anticipates that the review process will be a period of intensive and extensive further work involving responding to questions and requests for further information by the regulatory authority as well as preparing for and undergoing detailed inspections of the contract research organizations (CROs) that managed the trial, the Sponsor, the Trial Master File, a number of individual trial sites selected by the regulatory from among the 94 sites that participated in the trial, the GMP facility and manufacturing information.
공고 • Sep 13Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory BoardNorthwest Biotherapeutics announced that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine. The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.